Currently out of the existing stock ratings of Keay Nakae, 285 are a BUY (90.48%), 24 are a HOLD (7.62%), 6 are a SELL (1.9%).

Keay Nakae

Work Performance Price Targets & Ratings Chart

Analyst Keay Nakae, currently employed at CHARDAN CAPITAL, carries an average stock price target met ratio of 47.55% that have a potential upside of 38.1% achieved within 177 days.

Keay Nakae’s has documented 559 price targets and ratings displayed on 48 stocks. The coverage is on Healthcare, Financial Services, Consumer Cyclical sectors.

Most recent stock forecast was given on COYA, Coya Therapeutics, Common Stock at 12-Aug-2026.

Wall Street Analyst Keay Nakae

Analyst best performing recommendations are on STOK (STOKE THERAPEUTICS).
The best stock recommendation documented was for STOK (STOKE THERAPEUTICS) at 1/5/2026. The price target of $35 was fulfilled within 1 day with a profit of $2.45 (7.53%) receiving and performance score of 75.27.

Average potential price target upside

of $58.12 (63.28%) on MCRB (SERES THERAPEUTICS).
of $53.2 (28.51%) on EVLO (EVELO BIOSCIENCES).
of $50.57 (28.46%) on ALNY (ALNYLAM PHARMACEUTICALS).

ABUS Arbutus Biopharma Corp ARWR Arrowhead Pharmaceuticals AXLA Axcella Health DRNA Dicerna Pharmaceuticals EBS Emergent Biosolutions KLDO Kaleido Biosciences MESO Mesoblast Ltd OCGN Ocugen PEAR Pear Therapeutics SONN Sonnet Biotherapeutics Holdings EVLO Evelo Biosciences FBRX Forte Biosciences LJPC La Jolla Pharmaceutical Co PHGE Biomx PRQR ProQR Therapeutics BV CFRX ContraFect Corp FEMY Femasys NBSE NeuBase Therapeutics RNA Avidity Biosciences SABS SAB Biotherapeutics MCRB Seres Therapeutics SYBX Synlogic ALNY Alnylam Pharmaceuticals BTTX Better Therapeutics DYN Dyne Therapeutics GANX Gain Therapeutics KMDA Kamada OCX OncoCyte Corp SLN Silence Therapeutics PLC XCUR Exicure OMGA Omega Therapeutics IBIO Ibio ALUR Allurion Technologies COYA Coya Therapeutics, Common Stock NTBL Notable Labs OBIO Orchestra BioMed Holdings CLBS Caladrius Biosciences MBOT Microbot Medical MNPR Monopar Therapeutics ADMA ADMA Biologics ANRO Alto Neuroscience AX Axos Financial KRRO Frequency Therapeutics PHG Koninklijke Philips NV ADR RPRX Royalty Pharma Plc SON Sonoco Products Company STEM Stem STOK Stoke Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Keay Nakae (CHARDAN CAPITAL)